Covalon Technologies Ltd Stock Price, News & Analysis

Covalon Technologies (CVALF) has announced that results from a clinical study of its VALGuard® Vascular Access Line Guard will be presented at two major scientific meetings and is advancing towards publication. The independent study focused on reducing Central Line-Associated Blood Stream Infections (CLABSIs) across critical and acute care units. CLABSIs affect hundreds of thousands of patients annually with a 15-20% mortality rate. The research will be presented at the Association for Vascular Access Annual Scientific Meeting in September and the American Nurses Credentialing Center Magnet Pathway Conference in October, which attracts over 11,000 nursing professionals. Major U.S. hospitals are incorporating VALGuard® into their infection prevention programs to protect intravenous lines from contamination.

Covalon Technologies (TSXV: COV; OTCQX: CVALF), a medical technologies company, has scheduled the release of its Q2 Fiscal 2025 financial results for Wednesday, May 28, 2025, before markets open. The company will host a conference call and webcast at 8:30am ET on the same day to discuss the results.

Investors can participate through the webcast or by dialing into the conference call using the following numbers: North American Toll-Free: 1-800-549-8228, Toronto Local: 289-819-1520, or New York Local: 646-564-2877 (Conference ID: 92114). A recording will be available on Covalon's website, and financial statements can be accessed through SEDAR PLUS.

Covalon Technologies (CVALF) has engaged Origin Merchant Partners as its financial and strategic advisor to explore opportunities for maximizing shareholder value. The company is considering various options including joint ventures, strategic partnerships, acquisitions, mergers, licensing deals, NASDAQ listing, stock buybacks using its $18 million net cash balance, and potential spinoffs of its business segments. The company's Advanced Wound Care segment has grown over 4x in the U.S. market in four years, contributing $10 million in Adjusted EBITDA. The Vascular Access and Surgical Consumables segment has achieved over 50% compound annual growth in the U.S. market over the past three fiscal years. Management believes Covalon is undervalued, trading at a mid-single-digit Adjusted EBITDA multiple compared to higher-multiple med-tech peers.

Covalon Technologies Ltd. (CVALF) has announced the promotion of Kim Crooks to Chief Operating Officer (COO) and her appointment to the company's Board of Directors, effective immediately. Crooks, who rejoined Covalon in early 2024 as Senior Vice President – Operations, previously served as Vice President of Operations from 2012 to 2022. In her role, she has been overseeing production, operations, Quality Assurance, Quality Control, Regulatory Affairs, and Human Resources.

As part of her appointment, Crooks will receive 150,000 stock options vesting equally over three years at market price. Both her Board appointment and stock option grant are subject to TSX Venture Exchange approval.

Covalon Technologies (TSXV: COV; OTCQX: CVALF) will present at the 2025 Bloom Burton & Co. Healthcare Investor Conference in Toronto on May 6, 2025, at 2:30 pm ET. CEO Brent Ashton will lead the presentation in Room 104 B at the Metro Toronto Convention Centre.

The presentation will focus on Covalon's mission to prevent healthcare complications through patient-centered technologies. Ashton will discuss the company's strong financial position and growth drivers. The conference, running May 5-6, 2025, provides a platform for healthcare companies and investors to connect.

Investors can register for one-on-one meetings with Covalon's management. Those unable to attend can learn more about Covalon's solutions through their website and social media channels including LinkedIn, Facebook, Instagram, and X.

Covalon Technologies (TSXV: COV; OTCQX: CVALF) announced its participation in the Planet MicroCap Showcase: VEGAS 2025, scheduled for April 23, 2025, at 4:30 pm PST. CEO Brent Ashton will present the company's position as an undervalued, cash-rich healthcare company in the microcap sector.

Key highlights include:

• Strong financial position with over $17 million CAD cash, debt-free status, and consistent profitability
• Recognition as a 2025 OTCQX Best 50 Company and TSX Venture Top 50 company
• Focus on advanced wound care, vascular access, and surgical products
• Growing sales driven by healthcare provider and patient advocacy

The presentation will be accessible via webcast, with opportunities for 1x1 investor meetings at the Paris Hotel & Casino in Las Vegas.

Covalon Technologies (TSXV: COV; OTCQX: CVALF) has announced a significant competitive advantage following the April 2, 2025 US tariff announcements. The company's Canadian-manufactured medical products qualify for complete exemption from US tariffs under the United States-Mexico-Canada Agreement (USMCA) rules of origin requirements.

As the largest advanced wound care collagen dressing manufacturer in North America, Covalon stands to benefit substantially as competitors from the UK, Germany, and China face tariffs of 10%, 20%, and 54% respectively. The company maintains manufacturing operations in both Canada and the United States for its medical products, enabling it to maintain competitive pricing and uninterrupted access to the US market.

Covalon Technologies (TSXV: COV; OTCQX: CVALF) held its Fiscal 2024 Annual Meeting of Shareholders on March 19, 2025. The meeting saw shareholders voting in favor of all proposed items, including the election of the Board of Directors and appointment of auditors.

The meeting achieved a 40.839% participation rate, with 11,189,231 shares represented either in person or by proxy. Detailed voting results will be available on SEDAR+, and management's presentation can be accessed through Covalon's investor relations website.

Covalon Technologies (TSXV: COV; OTCQX: CVALF) has announced its annual shareholder meeting scheduled for March 19, 2025, at 2:00pm Eastern Time. The meeting will be held in a virtual-only format, featuring a presentation from newly appointed CEO Brent Ashton, followed by a Q&A session.

Shareholders can attend via live webcast at https://virtual-meetings.tsxtrust.com/en/1738 using Meeting ID 1738 and password 'covalon2025'. Registered shareholders and appointed proxyholders will have full participation rights, including voting capabilities. Non-registered shareholders must complete additional steps to vote, including self-appointment as proxyholder and registration with TSX Trust Company.